Trexquant Investment’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Trexquant Investment’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-22,277	Closed	-$141K	–	1427
2018 Q1	$141K	Sell	22,277 -4,855	-18%	-$40.2K	0.01%	995
2017 Q4	$219K	Buy	+27,132	New	+$253K	0.02%	898
2016 Q3	–	Sell	-6,860	Closed	-$291K	–	1174
2016 Q2	$291K	Buy	+6,860	New	+$374K	0.04%	674
2016 Q1	–	Sell	-11,325	Closed	-$704K	–	1330
2015 Q4	$704K	Buy	+11,325	New	+$797K	0.06%	550
2015 Q3	–	Sell	-14,172	Closed	-$1.38M	–	1421
2015 Q2	$1.38M	Buy	14,172 +12,278	+648%	+$1.17M	0.15%	216
2015 Q1	$177K	Buy	+1,894	New	+$161K	0.02%	936

Other funds holding MACK

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Trexquant Investment's MACK Position: Q2 2018 in Review

Trexquant Investment sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2018, closing a stake of 22,277 shares — an estimated $141K sold.

Trexquant Investment first reported a position in MACK in Q1 2015 and held it in 6 quarters. The position peaked at $1.38M in Q2 2015. 76 funds tracked by Wall St. Rank hold MACK as of Q2 2018.

Trexquant Investment reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Trexquant Investment sold 22,277 Merrimack Pharmaceuticals, Inc. shares in Q2 2018, an estimated $141K.
Trexquant Investment first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2015 and held it in 6 quarters.
Trexquant Investment's Merrimack Pharmaceuticals, Inc. position peaked at $1.38M in Q2 2015.
76 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2018.

Based on Trexquant Investment's 13F filing for Q2 2018, filed 7 Aug 2018.